Reference 2019-219

REF:            2019-219

Subject:        Treated patients for invasive aspergillosis

 

Request:

Within your health trust how many patients have you treated in the year 2018, regardless of reason;

  • Ambisome
  • Caspofungin (cancidas)
  • Cresemba
  • Noxafil/posaconazole
  • Voriconazole/VFEND
  • Zavicefta
  • Zerbaxa

If your trust is able to split by indication, please provide the following;

Within your health trust how many patients have you treated in the year 2018  for IA (invasive aspergillosis) with the following;

  • Cresemba
  • Ambisome (amphotericin B/amphotericin liposomal)
  • Voriconazole/VFEND
  • Caspofungin (cancidas)
  • Noxafil/posaconazole

Within your health trust how many patients have you treated in the year 2018  for cIAI (complicated intra-abdominal) with the following;

  • Ceftazidime-avibactam (Zavicefta)
  • Meropenem
  • Ceftolozane‒Tazobactam (Zerbaxa)

Within your health trust how many patients have you treated in the year 2018  for cUTI (complex urinary tract infection) with the following;

  • Ceftazidime-avibactam (Zavicefta)
  • Meropenem
  • Ceftolozane‒Tazobactam (Zerbaxa)

Within your health trust how many patients have you treated in the year 2018  for HAP/VAP (hospital acquired pneumonias and ventilated associated pneumonia) with the following;

  • Ceftazidime-avibactam (Zavicefta)
  • Meropenem
  • Ceftolozane‒Tazobactam (Zerbaxa)

 

Response:

Please find information attached.

2019-219 – FOI Request – Treated patients for invasive aspergillosis [142 kb] PDF